Last $0.71 USD
Change Today +0.0146 / 2.10%
Volume 475.2K
RNN On Other Exchanges
Symbol
Exchange
NYSE Amex
Frankfurt
As of 8:04 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Peter C. Brandt

Director, Member of Audit Committee and Member of Nominating & Corporate Governance Committee, Rexahn Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 53 board members in 4 different organizations across 6 different industries.

See Board Relationships
57$49,417

Background*

Mr. Peter C. Brandt served as an Interim Chief Executive Officer and Interim President at Epocrates Inc. from November 16, 2011 to March 27, 2012. Mr. Brandt served as the President and Chief Executive Officer of Noven Pharmaceuticals Inc. since April 2008. He has extensive business and industry experience. He spent 28 years at Pfizer. He served as President - U.S. Pharmaceuticals Operations at Pfizer Inc., where he helped deliver revenue and earnings growth while engineering ...

Read Full Background

Corporate Headquarters*

15245 Shady Grove Road
Rockville, Maryland 20850

United States

Phone: 240-268-5300
Fax: 240-268-5310

Board Members Memberships*

Former Chairman
Member of The Board of Trustees
2008-Present
Director
2010-Present
Director and Member of Audit & Compliance Committee
2010-Present
Director, Member of Audit Committee and Member of Nominating & Corporate Governance Committee
2011-2013
Former Chairman and Chairman of Compensation Committee

Education*

MBA
Columbia Business School
BA
University of Connecticut

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

Total Annual Cash Compensation$28,000
Total Calculated Compensation$49,417
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RNN:US $0.71 USD +0.0146

COMPETITOR COMPENSATION

There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REXAHN PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.